- Home
- IHS vs GLPG Comparison
IHS vs GLPG Comparison
Compare IHS & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- GLPG
- Stock Information
- Founded
- IHS 2001
- GLPG 1999
- Country
- IHS United Kingdom
- GLPG Belgium
- Employees
- IHS N/A
- GLPG N/A
- Industry
- IHS Telecommunications Equipment
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- IHS Telecommunications
- GLPG Health Care
- Exchange
- IHS Nasdaq
- GLPG Nasdaq
- Market Cap
- IHS 2.1B
- GLPG 2.1B
- IPO Year
- IHS 2021
- GLPG 2005
- Fundamental
- Price
- IHS $7.25
- GLPG $32.41
- Analyst Decision
- IHS Strong Buy
- GLPG Sell
- Analyst Count
- IHS 8
- GLPG 4
- Target Price
- IHS $9.78
- GLPG $25.33
- AVG Volume (30 Days)
- IHS 644.3K
- GLPG 274.2K
- Earning Date
- IHS 08-12-2025
- GLPG 07-23-2025
- Dividend Yield
- IHS N/A
- GLPG N/A
- EPS Growth
- IHS N/A
- GLPG N/A
- EPS
- IHS 0.33
- GLPG N/A
- Revenue
- IHS $1,731,025,000.00
- GLPG $323,674,692.00
- Revenue This Year
- IHS $1.97
- GLPG N/A
- Revenue Next Year
- IHS $5.50
- GLPG N/A
- P/E Ratio
- IHS $22.19
- GLPG N/A
- Revenue Growth
- IHS N/A
- GLPG 5.43
- 52 Week Low
- IHS $2.44
- GLPG $22.36
- 52 Week High
- IHS $7.52
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- IHS 61.78
- GLPG 53.76
- Support Level
- IHS $6.66
- GLPG $31.42
- Resistance Level
- IHS $7.52
- GLPG $32.43
- Average True Range (ATR)
- IHS 0.32
- GLPG 0.77
- MACD
- IHS 0.02
- GLPG -0.09
- Stochastic Oscillator
- IHS 78.23
- GLPG 56.92
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.